Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection
Transplant International · 2024
DOI: 10.3389/ti.2024.12847 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant International, 2024. Verfasst von A Zajacova und 15 weiteren Autor:innen. Beteiligte Einrichtung: Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czechia. Hauptthemen laut MEDLINE: Graft Rejection, Lung Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Histologic evaluation of allograft biopsies after lung transplantation has several limitations, suggesting that molecular assessment using tissue transcriptomics could improve biopsy interpretation. This single-center, retrospective cohort study evaluated discrepancies between the histology of transbronchial biopsies (TBBs) with no rejection (NR) and T-cell mediated rejection (TCMR) by molecular diagnosis. The accuracy of diagnosis was assessed based on response to treatment. 54 TBBs from Prague Lung Transplant Program obtained between December 2015 and January 2020 were included. Patients with acute cellular rejection (ACR) grade ≥ 1 by histology received anti-rejection treatment. Response to therapy was defined as an increase in FEV1 of ≥ 10% 4 weeks post-biopsy compared to the pre-biopsy value. Among the 54 analyzed TBBs, 25 (46%) were concordant with histology, while 29 (54%) showed discrepancies. ACR grade 0 was found in 12 TBBs (22%) and grade A1 ≥ 1 in 42 TBBs (78%). Treatment response was present in 14% in the NR group and in 50% in the TCMR group ( p = 0.024). Our findings suggest that low-grade acute cellular rejection is less likely to be associated with molecular TCMR, which might better identify lung transplant recipients who benefit from therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czechia.
- Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada.
- Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia.
- Second Faculty of Medicine, Charles University, Prague, Czechia.
- Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czechia.
Zitieren
APA
Zajacova, A., Mackova, M., Halloran, K., Gauthier, P., Balko, J., Guney, M., Rakita, D., Svorcova, M., Kolarik, J., Vachtenheim, J., Pozniak, J., Simonek, J., Fila, L., Lischke, R., Halloran, P. F., & Havlin, J. (2024). Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection. Transplant International. https://doi.org/10.3389/ti.2024.12847
Vancouver
Zajacova A, Mackova M, Halloran K, Gauthier P, Balko J, Guney M, et al. Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection. Transplant International. 2024. doi:10.3389/ti.2024.12847
BibTeX
@article{Zajacova2024,
author = {Zajacova, A and Mackova, M and Halloran, K and Gauthier, P and Balko, J and Guney, M and Rakita, D and Svorcova, M and Kolarik, J and Vachtenheim, J and Pozniak, J and Simonek, J and Fila, L and Lischke, R and Halloran, P F and Havlin, J},
title = {Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12847}
}
EUVIMED